CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 276 enrolled
Drug / intervention
MMH-MAP +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03815292
NCT03815292Phase 3Completed
CompareCT.gov

Multicenter Double-blind Placebo-controlled Randomized Parallel-group Clinical Study of Efficacy and Safety of MMH-MAP in the Treatment of Mild Cognitive Impairment in Subjects in Early Rehabilitation Period of Ischemic Stroke

Materia Medica Holding·interventional·Posted Jan 24, 2019·Updated Feb 23, 2021

In Brief

A Phase 3 clinical trial evaluating MMH-MAP and Placebo for Mild Cognitive Impairment and Ischemic Stroke. Completed, enrolled 276 participants across 28 sites.

Detailed Summary

The purpose of this study is: * to evaluate efficacy of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke * to evaluate safety of MMH-MAP in the treatment of mild cognitive impairment in subjects in early rehabilitation period of ischemic stroke

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMild Cognitive Impairment, Ischemic Stroke
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
20192020202120222023202420252026
First PostedJan 24, 2019
Enrollment StartOct 19, 2018
Primary CompletionJan 27, 2020
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 7.4 years ago

Interventions

MMH-MAPdrug

Oral administration

Placebodrug

Oral administration